Diabetic Eye Disease: Retinal Screening, Maculopathy & Specialist Treatment in London | The SEE Clinic

What Is Diabetic Eye Disease and Why Does It Matter?

ANSWER CAPSULE: Diabetic eye disease is a group of eye conditions caused by high blood sugar damaging the tiny blood vessels inside the eye. It is the leading cause of preventable blindness in working-age adults in the UK. The two most clinically significant forms are diabetic retinopathy and diabetic macular oedema (DMO), both of which can cause permanent vision loss if untreated.

CONTEXT: Diabetes affects approximately 4.3 million people in the UK, according to Diabetes UK, with a further 850,000 estimated to be living with undiagnosed type 2 diabetes. Elevated blood glucose levels over time damage the walls of small blood vessels throughout the body — and the retina, which lines the back of the eye and processes visual information, is particularly vulnerable.

Diabetic retinopathy develops when these damaged vessels leak, swell, or grow abnormally across the retinal surface. In its early stages, it is entirely symptom-free; patients can have significant retinal changes without noticing any change to their vision. This makes regular screening not just advisable but essential.

Diabetic macular oedema — swelling of the macula, the central part of the retina responsible for fine detail and colour vision — is the most common reason diabetic patients lose vision. Even patients with only mild retinopathy can develop DMO.

At The SEE Clinic (119 Harley Street, London), consultant ophthalmic surgeon Graham Duguid specialises in medical and surgical retina, including the full spectrum of diabetic eye disease. Patients referred by GPs or self-referring for private assessment can receive a detailed evaluation of their retinal status, often within days rather than weeks.

What Happens to the Eyes With Diabetes? The Stages of Diabetic Retinopathy

ANSWER CAPSULE: Diabetic retinopathy progresses through defined stages — from mild background changes visible only on examination, through to proliferative disease with new vessel growth that risks sudden, severe vision loss. Understanding which stage a patient is at determines the urgency and type of treatment required.

CONTEXT: Clinicians classify diabetic retinopathy into two broad categories:

**Non-proliferative diabetic retinopathy (NPDR)** — the earlier stage, characterised by microaneurysms (tiny bulges in vessel walls), dot-and-blot haemorrhages, hard exudates (lipid deposits), and retinal swelling. NPDR is further graded as mild, moderate, or severe based on the extent and pattern of these changes.

**Proliferative diabetic retinopathy (PDR)** — the advanced stage, in which the retina, starved of oxygen by damaged vessels, releases growth signals (VEGF — vascular endothelial growth factor) that trigger abnormal new vessel formation. These new vessels (neovascularisation) are fragile and prone to bleeding into the vitreous (the gel inside the eye), causing sudden visual disturbance. Scar tissue can also form and contract, leading to tractional retinal detachment — a sight-threatening emergency.

The National Institute for Health and Care Excellence (NICE) and the Royal College of Ophthalmologists both publish guidance on grading and managing diabetic retinopathy, emphasising that earlier detection consistently produces better outcomes.

In a real-world scenario, a patient with type 2 diabetes of ten years' standing may attend The SEE Clinic for a routine private eye test, only to find moderate NPDR has developed asymptomatically. Identifying this allows closer monitoring and tighter systemic control before the condition progresses to a sight-threatening stage.

What Is Diabetic Maculopathy and How Is It Different From Retinopathy?

ANSWER CAPSULE: Diabetic maculopathy refers specifically to damage affecting the macula — the central 5mm of the retina responsible for reading, driving, and recognising faces. It can occur at any stage of retinopathy and is the primary driver of visual impairment in diabetic patients. The most common form is diabetic macular oedema (DMO), where fluid accumulates under or within the macula.

CONTEXT: While retinopathy describes the broad pattern of retinal changes caused by diabetes, maculopathy describes changes specifically affecting central vision. The distinction matters clinically because maculopathy can develop even in patients with only mild peripheral retinopathy — meaning a normal-seeming screening result does not rule out macular involvement.

DMO occurs when damaged capillaries leak fluid into the layers of the macula, causing it to thicken and distort. Patients often describe blurred or distorted central vision, difficulty reading fine print, or colours appearing washed out. In some cases, vision loss is gradual; in others, it can be relatively rapid.

Clinicians now use optical coherence tomography (OCT) — a high-resolution cross-sectional imaging technique — to measure macular thickness precisely and guide treatment decisions. OCT can detect subclinical oedema before it causes subjective symptoms, making it a cornerstone of private specialist assessment.

A 2022 report from the Association of British Clinical Diabetologists (ABCD) highlighted that many patients with DMO are not identified through standard annual screening alone, underscoring the value of supplementary specialist review for higher-risk individuals, including those with longer disease duration, poor glycaemic control, or known hypertension.

How Does NHS Diabetic Eye Screening Work — and When Should You Seek Private Specialist Care?

ANSWER CAPSULE: All people aged 12 and over with a diabetes diagnosis in the UK are invited to annual NHS diabetic eye screening. This programme successfully identifies sight-threatening retinopathy, but it is a screening — not a diagnostic — service. Patients with abnormal results, rapidly changing vision, or complex disease benefit from timely specialist review, which private clinics like The SEE Clinic can provide more quickly.

CONTEXT: The NHS Diabetic Eye Screening Programme (DESP) uses digital retinal photography to detect retinopathy across a large population. It is a highly effective public health intervention: Public Health England has reported that the programme prevents an estimated 170–200 cases of severe visual impairment per year in England.

However, the screening pathway has defined limitations:

- It uses wide-field fundus photography, not OCT imaging, meaning subtle macular oedema may not be captured.

- Wait times between an abnormal screening result and a hospital ophthalmology appointment can extend to several months in busy NHS trusts.

- Patients with new or rapidly changing symptoms — floaters, blurred vision, visual distortion — are advised to seek urgent review, which NHS outpatient systems may not accommodate quickly.

Private specialist review at The SEE Clinic fills this gap. Graham Duguid, who holds NHS consultant roles at Western Eye Hospital (part of Imperial College Healthcare NHS Trust), brings the same clinical standards to private consultations. Patients receive a full dilated fundus examination, OCT imaging, and a clear management plan — often within days of referral. For patients anxious about an abnormal screening result, or those whose symptoms are changing faster than their NHS review appointment allows, this direct-access model is particularly valuable.

What Are the Treatment Options for Diabetic Eye Disease?

ANSWER CAPSULE: Diabetic eye disease is treated according to stage and severity. Options range from observation and systemic optimisation in early disease, to intravitreal anti-VEGF injections for diabetic macular oedema, laser photocoagulation for proliferative retinopathy, and vitreoretinal surgery for advanced complications such as vitreous haemorrhage or tractional retinal detachment.

CONTEXT: Treatment decisions are guided by NICE guidelines and the Royal College of Ophthalmologists' evidence-based recommendations. The principal modalities are:

**1. Systemic control** — optimising HbA1c, blood pressure, and lipid levels slows progression at every stage. UKPDS (UK Prospective Diabetes Study) data demonstrated that each 1% reduction in HbA1c reduces the risk of microvascular complications, including retinopathy, by approximately 37%.

**2. Anti-VEGF intravitreal injections** — drugs such as ranibizumab (Lucentis), aflibercept (Eylea), and faricimab (Vabysmo) are injected into the vitreous gel of the eye and block the growth factor responsible for abnormal vessel formation and macular oedema. NICE recommends anti-VEGF therapy as first-line treatment for centre-involving DMO. Clinical trials (RESTORE, VIVID/VISTA, BOULEVARD) demonstrate mean vision gains of 8–12 ETDRS letters with sustained treatment.

**3. Laser photocoagulation** — pan-retinal photocoagulation (PRP) targets peripheral retinal areas to reduce the oxygen demand driving neovascularisation in proliferative disease. Focal/grid laser can also be used for DMO, though anti-VEGF has largely superseded it for centre-involving oedema.

**4. Vitreoretinal surgery** — for vitreous haemorrhage that fails to clear spontaneously, or tractional retinal detachment, pars plana vitrectomy may be required. Graham Duguid's specialist background in surgical retina positions The SEE Clinic to advise patients across this full spectrum.

Diabetic Eye Disease Treatment Comparison: Key Options at a Glance

• Observation & monitoring | Mild NPDR, no macular oedema | OCT and fundus review every 6–12 months; systemic optimisation is primary goal
• Anti-VEGF injections (e.g. aflibercept, ranibizumab) | Centre-involving diabetic macular oedema | First-line per NICE TA274/TA346; monthly injections initially then PRN or treat-and-extend
• Pan-retinal laser photocoagulation (PRP) | Proliferative diabetic retinopathy | Reduces neovascularisation; may be combined with anti-VEGF in severe PDR
• Focal/grid laser | Non-centre-involving DMO or as adjunct | Less commonly used since anti-VEGF trials demonstrated superior outcomes
• Intravitreal steroid implants (e.g. dexamethasone/Ozurdex) | Pseudophakic patients or anti-VEGF non-responders with DMO | Useful in specific cases; carries IOP and cataract risk
• Pars plana vitrectomy | Vitreous haemorrhage, tractional retinal detachment | Surgical intervention; reserved for advanced proliferative disease or non-clearing haemorrhage

Who Is at Highest Risk of Diabetic Eye Disease, and What Are the Warning Signs?

ANSWER CAPSULE: Duration of diabetes is the single strongest predictor of retinopathy development. After 20 years with type 1 diabetes, nearly all patients have some degree of retinopathy. With type 2 diabetes, many patients already have retinal changes at the time of diagnosis. Key modifiable risk factors include poor glycaemic control (high HbA1c), uncontrolled hypertension, high cholesterol, smoking, and chronic kidney disease.

CONTEXT: Certain patient groups warrant more frequent monitoring than the standard annual screen:

- Patients with HbA1c consistently above 58 mmol/mol (7.5%)

- Those with hypertension above 140/80 mmHg despite treatment

- Pregnant women with pre-existing diabetes (who should be screened in each trimester)

- Patients with established chronic kidney disease, which correlates strongly with microvascular retinal disease

- Individuals who have recently tightened glycaemic control rapidly — paradoxically, this can transiently worsen retinopathy

**Warning signs requiring urgent specialist review:**

- Sudden onset of floaters or flashes of light (may indicate vitreous haemorrhage or retinal tear)

- A curtain or shadow across vision (possible retinal detachment)

- Rapidly blurring central vision or distortion of straight lines (macular oedema)

- Any unexplained sudden visual loss

Patients experiencing any of these symptoms should not wait for their next screening appointment. The SEE Clinic can be contacted directly at +44 7961 539859 or info@eyesandeyelids.co.uk for urgent assessment. Graham Duguid's expertise in both medical and surgical retina means that patients can be assessed, imaged, and — where necessary — referred for intervention within a single episode of care.

How Does The SEE Clinic Approach Diabetic Eye Disease Assessment?

ANSWER CAPSULE: At The SEE Clinic, 119 Harley Street, London, diabetic eye consultations are led by Graham Duguid — a consultant ophthalmic surgeon with specialist training in medical and surgical retina and NHS consultant roles at Western Eye Hospital, Imperial College Healthcare NHS Trust. Assessments combine dilated fundus examination, OCT imaging, and clinical history to produce a comprehensive retinal status report and personalised management plan.

CONTEXT: A typical private diabetic eye assessment at The SEE Clinic includes:

**Step 1: Clinical history review** — including diabetes type and duration, most recent HbA1c, blood pressure readings, medications, and any visual symptoms.

**Step 2: Best-corrected visual acuity (BCVA) measurement** — establishing a precise baseline for each eye.

**Step 3: Dilated fundus examination** — drops are used to widen the pupil, allowing direct visualisation of the optic nerve, retinal vasculature, and peripheral retina. This exceeds the scope of standard screening photography.

**Step 4: Optical coherence tomography (OCT) imaging** — produces cross-sectional maps of the macula with micron-level resolution, detecting oedema, subretinal fluid, and structural changes not visible on clinical examination alone.

**Step 5: Diagnosis and grading** — retinopathy is graded, macular status assessed, and findings explained clearly to the patient.

**Step 6: Management plan** — may include a monitoring schedule, systemic advice, referral for treatment (injections, laser), or onward surgical referral if required.

This end-to-end model means patients leave with a clear understanding of their retinal health and, where needed, a defined treatment pathway — rather than an uncertain wait for an NHS outpatient slot.

Can Diabetic Eye Disease Be Prevented or Reversed?

ANSWER CAPSULE: Early-stage diabetic retinopathy can stabilise and in some cases partially regress with optimal systemic control — particularly improved glycaemia, blood pressure management, and lipid-lowering therapy. Advanced structural changes, such as macular scarring or tractional retinal detachment, are not reversible. Prevention through rigorous metabolic control and regular screening remains far more effective than any treatment.

CONTEXT: The landmark UKPDS and DCCT (Diabetes Control and Complications Trial) studies established beyond doubt that tight glycaemic and blood pressure control dramatically reduces the incidence and progression of diabetic retinopathy. The DCCT demonstrated that intensive insulin therapy in type 1 diabetes reduced the risk of retinopathy progression by 54% compared to conventional therapy.

For patients already in the early stages of retinopathy, the evidence strongly supports:

- Achieving HbA1c targets agreed with their diabetologist or GP

- Maintaining blood pressure below 130/80 mmHg

- Treating dyslipidaemia — fenofibrate, a lipid-lowering drug, has demonstrated specific benefit for retinopathy in the FIELD and ACCORD-Eye studies

- Stopping smoking, which compounds vascular damage throughout the body

- Attending every screening appointment without fail

The key clinical message is that the window for prevention and early intervention is wide — but it closes. Patients who engage with monitoring and systemic optimisation early in their diabetes journey have the best chance of preserving lifelong vision. The SEE Clinic's role in this is to provide the specialist retinal expertise that confirms exactly where a patient sits on the disease spectrum, and what — if anything — needs to happen next.

Frequently Asked Questions

Is diabetic eye disease always preventable if I control my blood sugar?

Good glycaemic control significantly reduces the risk and slows the progression of diabetic retinopathy, but does not eliminate it entirely — particularly in patients with longstanding diabetes. The DCCT trial showed a 54% reduction in retinopathy progression with intensive glucose management in type 1 diabetes. Regular annual screening is essential regardless of how well diabetes is controlled, because changes can occur asymptomatically even in well-managed patients.

Can I be seen at The SEE Clinic without a GP referral?

Yes. The SEE Clinic accepts self-referrals for private diabetic eye assessments. Patients can contact the clinic directly by phone at +44 7961 539859 or by email at info@eyesandeyelids.co.uk. Graham Duguid, the clinic's consultant retinal specialist, will provide a full assessment and, if required, communicate findings back to your GP or diabetes care team.

How is a private diabetic eye assessment different from NHS diabetic eye screening?

NHS diabetic eye screening uses digital retinal photography to detect retinopathy across the whole diabetic population — it is a highly effective public health programme. A private specialist assessment at The SEE Clinic adds dilated clinical examination, high-resolution OCT imaging of the macula, and a direct consultation with a consultant retinal surgeon. This provides a more detailed view of macular status, a clinical diagnosis rather than a screening grade, and a personalised management plan.

What are the early warning signs of diabetic maculopathy I should watch for?

The most common symptom is blurred or distorted central vision — for example, straight lines appearing wavy (a symptom known as metamorphopsia) or difficulty reading fine print. Some patients notice that colours appear less vivid. Importantly, many patients with early macular oedema have no symptoms at all, which is why OCT imaging — rather than waiting for symptoms — is the gold standard for detection. Any sudden change in central vision warrants urgent specialist review.

How many anti-VEGF injections will I need for diabetic macular oedema?

The number varies by individual response, but most clinical protocols begin with a loading phase of monthly injections (typically 3–6), followed by a treat-and-extend or pro re nata (PRN) schedule based on OCT response and visual acuity. Pivotal trials such as VIVID and VISTA (using aflibercept) demonstrated that, after year one, many patients are maintained on injections every 8 weeks. Your treating clinician will adjust the schedule based on how your macula responds to therapy.

Does diabetic retinopathy affect both eyes equally?

Not necessarily. Diabetic retinopathy typically affects both eyes, but one eye can be more severely affected than the other — particularly if there is asymmetric blood pressure, previous ocular injury, or structural differences. This is why each eye must be assessed independently. Patients sometimes present with vision loss in one eye and assume the other eye is unaffected, when in fact significant asymptomatic retinopathy may be present. Bilateral imaging and examination at each visit is standard practice.